Picture of Jubilant Pharmova logo

JUBLPHARMA — Jubilant Pharmova News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

India's Jubilant Pharmova reports narrower fourth-quarter loss

BENGALURU, May 29 (Reuters) - Indian pharmaceutical firm
Jubilant Pharmova  JUBA.NS  reported a narrower fourth-quarter
loss on Wednesday, aided by strong demand for drugs that contain
radioactive ingredients. 
    The company's consolidated net loss narrowed to 586 million
rupees ($7 million) in the January to March period, compared
with a loss of 979 million rupees a year ago. 
    Jubilant Pharmova, involved in the manufacturing and supply
of radiopharmaceuticals with a network of 46 radio-pharmacies in
the U.S., said it is on track to launch new products in this
segment in the medium-term. 
    Sales rose 5% to 17.46 billion rupees in the fourth quarter,
lifted by an 18.6% rise in the key radiopharma business, which
involves developing medications used to diagnose or treat
diseases such as cancer, and made up nearly half of the sales. 
    Revenue from segments that make copycat drugs and medicines
used for allergy immunotherapy rose 0.8% and 14%, respectively,
during the quarter. 
    The drugmaking arm of the polymers-to-pizza Jubilant Bhartia
group declared a dividend of 5 rupees per share. 
    Its shares ended 0.4% higher after results and are up 29.5%
so far this year.   

($1 = 83.3335 Indian rupees)

 (Reporting by Hritam Mukherjee in Bengaluru; Editing by Mrigank
Dhaniwala)
 ((Hritam.Mukherjee@thomsonreuters.com; X: @MukherjeeHritam;))

Recent news on Jubilant Pharmova

See all news